Horizon Pharma PLC (NASDAQof “Buy” from the eleven research firms that are presently covering the stock, MarketBeat.Com reports. Two analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $37.88.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) opened at 17.06 on Thursday. The stock’s market capitalization is $2.72 billion. The company’s 50-day moving average price is $22.48 and its 200 day moving average price is $29.63. Horizon Pharma PLC has a one year low of $11.87 and a one year high of $39.49.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.32 by $0.07. During the same period last year, the business earned $0.21 EPS. The company earned $172.80 million during the quarter, compared to the consensus estimate of $156.41 million. The firm’s quarterly revenue was up 161.4% compared to the same quarter last year. Analysts anticipate that Horizon Pharma PLC will post $1.39 EPS for the current year.
In other Horizon Pharma PLC news, EVP Jeffrey W. Sherman sold 7,750 shares of Horizon Pharma PLC stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $31.78, for a total transaction of $246,295.00. Following the completion of the sale, the executive vice president now directly owns 105,132 shares in the company, valued at approximately $3,341,094.96. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
HZNP has been the topic of several recent research reports. Leerink Swann reiterated a “positive” rating and set a $37.00 target price on shares of Horizon Pharma PLC in a research report on Tuesday, July 7th. Brean Capital restated a “buy” rating and set a $40.00 price target (up previously from $33.00) on shares of Horizon Pharma PLC in a report on Wednesday, July 8th. Piper Jaffray reiterated a “positive” rating and issued a $38.00 target price on shares of Horizon Pharma PLC in a report on Tuesday, July 14th. Guggenheim restated a “buy” rating on shares of Horizon Pharma PLC in a report on Monday, August 3rd. Finally, JMP Securities started coverage on Horizon Pharma PLC in a research report on Wednesday, September 9th. They set an “outperform” rating and a $39.00 target price for the company.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical firm focused on identifying, developing, acquiring or in- commercializing and licensing differentiated products that address unmet medical needs. The Company markets a portfolio of products in orphan and arthritis, inflammation disorders. The Company’s the United States advertised products are ACTIMMUNE (NASDAQ:HZNP), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release pills and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, gets the Usa rights to VIMOVO, gets the Usa rights and has the Usa rights to PENNSAID 2%.